In the PLATO (PLATelet inhibition and patient Outcomes) trial, GDF-15 was an independent risk factor for major bleeding across different bleeding locations, as well as for the composite endpoint of cardiovascular death, spontaneous myocardial infarction and stroke in ACS patients. Here, GDF15 is linked to Stroke.